NICE approves dabigatran in atrial fibrillation

Dabigatran etexilate (Pradaxa) can now be prescribed on the NHS to prevent stroke associated with atrial fibrillation (AF).

Pradaxa: only the 110mg and 150mg capsules are licensed for stroke prevention in patients with atrial fibrillation
Pradaxa: only the 110mg and 150mg capsules are licensed for stroke prevention in patients with atrial fibrillation

Dabigatran etexilate (Pradaxa), is recommended by the National Institute for Health and Care Excellence (NICE) as an option to prevent stroke and systemic embolism in patients with non-valvular AF who have ≥1 of the following risk factors:

  • Previous stroke, transient ischaemic attack or systemic embolism
  • Left ventricular ejection fraction <40%
  • Symptomatic heart failure (NYHA class II or above)
  • Age ≥75 years
  • Age ≥65 years with one of the following: diabetes, coronary artery disease or hypertension.

The thrombin inhibitor is also approved by NICE for the prevention of venous thromboembolic events in adults who have undergone elective total hip or knee replacement surgery.

Further details

NICE guidance on dabigatran for stroke prevention in AF

NICE guidance on dabigatran for VTE prevention

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

NICE recommends dabigatran as an option in thromboembolism

NICE recommends dabigatran as an option in thromboembolism

NICE has recommended that dabigatran etexilate (Pradaxa)...

Eliquis approved for DVT and PE

Eliquis approved for DVT and PE

Eliquis (apixaban) is now licensed for the treatment...

Pradaxa now indicated for DVT and PE

Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment...

Pradaxa: safety update owing to risk of serious haemorrhage

Pradaxa: safety update owing to risk of serious haemorrhage

The MHRA has issued updated safety advice for the anticoagulant...

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa (dabigatran) is now licensed for the prevention...

Pradaxa

Pradaxa (dabigatran etexilate) is the first oral direct...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more